ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Research context
ReNeuron Group plc appears in PyInvesting’s London Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
ReNeuron Group plc is currently in a long term downtrend where the price is trading 1.7% below its 200 day moving average.
From a valuation standpoint, the stock is 14.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 509.9.
ReNeuron Group plc's total revenue sank by 0.0% to $3M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 55.7% to $-1M since the same quarter in the previous year.
Based on the above factors, ReNeuron Group plc gets an overall score of 1/5.